Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) for the reporting period ending December 12, 2016, with the earliest event reported on December 9, 2016. The filing discloses the closing of a strategic investment transaction with Tianjin Pharmaceuticals Group International Holdings Co., LTD. ("Tianjin").
Key Financial Metrics and Transaction Details
The filing details a capital raise event rather than standard operating financial metrics. The transaction components are as follows:
- Common Stock Issuance: 28,500,000 shares issued at a price of $0.253 per share.
- Preferred Stock Issuance: 1,000,000 shares of Series A 4.5% Convertible Preferred Stock with a stated value of $12.7895 per share.
- Conversion Rights: The Preferred Stock is immediately convertible into an aggregate of 50,551,383 shares of Common Stock, subject to voting interest limitations.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or liquidity ratios.
- Debt and Margins: The filing text does not provide data on debt levels or profit margins.
Material Changes
The primary material change is the significant dilution of existing shareholders and the alteration of the company's capital structure due to the issuance of 28.5 million common shares and 1 million shares of convertible preferred stock. Additionally, the company filed a Certificate of Designation with the State of Delaware on December 9, 2016, to establish the rights and privileges of the new Series A Preferred Stock.
Guidance, Outlook, and Risks
Management Commentary: The transaction is characterized as a "strategic investment." A press release dated December 12, 2016, was issued to announce the closing (Exhibit 99.01).
Risks and Contingencies: The conversion of the Series A Preferred Stock into common stock is subject to certain limitations based on Tianjin's voting interest. The filing includes standard Regulation FD disclosures stating that the press release information is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Guidance: The filing text does not provide specific forward-looking financial guidance or operational outlook beyond the completion of this investment.
Investor Verification Checklist
- Verify the total capital raised by calculating the aggregate value of the common stock and preferred stock issued.
- Review the "Certificate of Designation" (Exhibit 3.01) to understand the specific voting and conversion limitations on the Series A Preferred Stock.
- Confirm the post-transaction share count and the resulting ownership percentage of Tianjin Pharmaceuticals Group.
- Examine the Securities Purchase Agreement (referenced in the Prior 8-K) for any covenants or conditions attached to the investment.
- Check subsequent filings for the actual conversion of the preferred stock into common shares.